Benzinga | Jun 22, 2021 09:14AM EDT

Edgewise Therapeutics To Present At PPMD Annual Conference And New Directions In Biology And Disease Of Skeletal Muscle Conference

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the company will present at the 2021 PPMD Annual Conference and the 2021 New Directions in Biology and Disease of Skeletal Muscle Conference.

2021 PPMD Annual Conference

Presentation: An Introduction to Edgewise Therapeutics

Presenter: Alan Russell, Ph.D., Chief Scientific Officer, Edgewise Therapeutics

Presentation: Development of a Novel Therapeutic for Duchenne, Becker and other Muscular Dystrophies

Date: Wednesday, June 23, 2021 at 6:40 pm ET

Presenter: Joanne Donovan, M.D., Ph.D., Chief Medical Officer, Edgewise Therapeutics

2021 New Directions in Biology and Disease of Skeletal Muscle Conference

Presentation: Selective Inhibition of Fast Skeletal Muscle Myosin as a Novel Therapeutic Strategy for Muscular Dystrophy

Date: Monday, June 28, 2021 at 12:10 p.m. ET

Presenter: Alan Russell, Ph.D., Chief Scientific Officer, Edgewise Therapeutics

The presentation at the New Directions conference describes the potential of selective fast myosin inhibition to provide broad protection of muscle in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

The presentations will be available on the Edgewise website after they are presented.